10th Annual FDA/Alzheimer’s Disease Allies Meeting
The ACT-AD 10th Annual FDA/AD Allies Meeting was held on Thursday, November 16, 2017. At the meeting, representatives from the National Institutes of Health (NIH) and the U.S. Food and Drug Administration (FDA) meet with advocates, researchers, and industry representatives to discuss the latest knowledge in Alzheimer’s disease research. The meeting emphasized the reciprocal connection between brain centers that govern emotion and cognition; highlighted the earliest manifestations of behavioral and neuropsychiatric symptoms in Alzheimer’s disease pathology; and examined how these changes may serve as early warning signs of future cognitive decline. We’ll give more updates in the next couple of weeks.
More Upcoming Events
“If You Build It, Will They Come?” Strategies for Alzheimer’s Disease Clinical Trial Recruitment WebinarThe Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) Coalition for an educational webinar on clinical trial…